New pharmacologic agents in the treatment of asthma.
This article will review four new medications for the treatment of asthma. Extensive studies have been undertaken with these medications to demonstrate their efficacy. All these agents, in use in other countries, are presently in different stages of review by the Food and Drug Administration. This review will give physicians an understanding of these medications, so when they are approved in the United States, the clinician will have an idea of their proper place in treatment of the asthmatic patient.
Blaiss
M S
MS
Division of Clinical Immunology, University of Tennessee, Memphis 38105-4526.
D000318:Adrenergic beta-Agonists / Q000737:chemistry / Q000627:therapeutic use; D000420:Albuterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D004983:Ethanolamines / Q000737:chemistry / Q000627:therapeutic use; D000068759:Formoterol Fumarate; D006801:Humans; D017835:Nedocromil; D010793:Phthalazines / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use; D000068299:Salmeterol Xinafoate
D000318:Adrenergic beta-Agonists; D004983:Ethanolamines; D010793:Phthalazines; D015363:Quinolones; D017835:Nedocromil; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate; C020976:azelastine